- Home
- LANV vs SLS Comparison
LANV vs SLS Comparison
Compare LANV & SLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LANV
- SLS
- Stock Information
- Founded
- LANV 2015
- SLS 2012
- Country
- LANV China
- SLS United States
- Employees
- LANV N/A
- SLS N/A
- Industry
- LANV Blank Checks
- SLS Biotechnology: Pharmaceutical Preparations
- Sector
- LANV Finance
- SLS Health Care
- Exchange
- LANV Nasdaq
- SLS Nasdaq
- Market Cap
- LANV 244.4M
- SLS 208.0M
- IPO Year
- LANV N/A
- SLS N/A
- Fundamental
- Price
- LANV $2.01
- SLS $1.55
- Analyst Decision
- LANV
- SLS Strong Buy
- Analyst Count
- LANV 0
- SLS 1
- Target Price
- LANV N/A
- SLS $7.00
- AVG Volume (30 Days)
- LANV 38.9K
- SLS 3.9M
- Earning Date
- LANV 08-29-2025
- SLS 11-12-2025
- Dividend Yield
- LANV N/A
- SLS N/A
- EPS Growth
- LANV N/A
- SLS N/A
- EPS
- LANV N/A
- SLS N/A
- Revenue
- LANV $341,783,911.00
- SLS N/A
- Revenue This Year
- LANV N/A
- SLS N/A
- Revenue Next Year
- LANV $6.90
- SLS N/A
- P/E Ratio
- LANV N/A
- SLS N/A
- Revenue Growth
- LANV N/A
- SLS N/A
- 52 Week Low
- LANV $1.32
- SLS $0.77
- 52 Week High
- LANV $2.69
- SLS $2.48
- Technical
- Relative Strength Index (RSI)
- LANV 49.38
- SLS 42.48
- Support Level
- LANV $1.83
- SLS $1.45
- Resistance Level
- LANV $2.18
- SLS $1.65
- Average True Range (ATR)
- LANV 0.16
- SLS 0.11
- MACD
- LANV -0.00
- SLS -0.00
- Stochastic Oscillator
- LANV 56.74
- SLS 38.80
About LANV Lanvin Group Holdings Limited
Lanvin Group Holdings Ltd engages in offering products ranging from apparel to leather goods, footwear, and accessories. The firm is operating mainly 5 portfolio brands, namely Lanvin, Wolford, Sergio Rossi, St. John, and Caruso. It derives the majority of its revenue from the Wolford segment.
About SLS SELLAS Life Sciences Group Inc.
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.